TY - CHAP M1 - Book, Section TI - Chapter 11. Cardiovascular Pharmacogenomics A1 - Aquilante, Christina L. A1 - Page, Robert L. A2 - Bertino, Joseph S. A2 - DeVane, C. Lindsay A2 - Fuhr, Uwe A2 - Kashuba, Angela D. A2 - Ma, Joseph D. PY - 2013 T2 - Pharmacogenomics: An Introduction and Clinical Perspective AB - Identify key candidate genes and polymorphisms that influence the pharmacokinetics, clinical response, and toxicity of cardiovascular medications.Describe, in depth, how key polymorphisms affect the pharmacokinetics, clinical response, and toxicity of cardiovascular medications such as clopidogrel, statins, and β-blockers.Discuss the role of genome-wide association studies in identifying genes and polymorphisms associated with response to cardiovascular medications.Weigh the evidence of available pharmacogenomic literature to determine the clinical utility of genetic testing in the management of cardiovascular diseases.Using a case-based approach, illustrate how genomic information may be used to guide drug selection and management of clopidogrel and statins. SN - PB - The McGraw-Hill Companies CY - New York, NY Y2 - 2024/03/28 UR - accesspharmacy.mhmedical.com/content.aspx?aid=56876674 ER -